Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity

Abstract excerpt

Abstract Replication‐incompetent adenovirus (Ad) vector and mRNA‐lipid nanoparticle (LNP) constructs represent two modular vaccine platforms that have attracted substantial interest over the past two decades. Due to the COVID‐19 pandemic and the rapid development of multiple successful vaccines based on these technologies, there is now clear real‐world evidence of the utility and efficacy of these platforms....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to RNA Interference and Gene Delivery
• Share to Virus-based gene therapy research